Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Abstract Pancreatic cancer is a dismal disease with a mortality rate almost similar to its incidence rate. To date, there are neither validated predictive nor prognostic biomarkers for this lethal disease. Thus, the aim of the present study was to retrospectively investigate the capability of bioche...
Guardado en:
Autores principales: | Daniela Bianconi, Gerwin Heller, Daniel Spies, Merima Herac, Andreas Gleiss, Sandra Liebmann-Reindl, Matthias Unseld, Markus Kieler, Werner Scheithauer, Berthold Streubel, Christoph C. Zielinski, Gerald W. Prager |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ad7dec37c3fb48049fe3aced16deae55 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun S, et al.
Publicado: (2014) -
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021) -
Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
por: Michael Pigula, et al.
Publicado: (2021) -
Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
por: Genta Ito, et al.
Publicado: (2021)